Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12451876 | 0.87 | HDAC1 (0.66) | HDAC1RAB9AROCK2KMT2APOLB | |
| SCHEMBL16915090 | 0.85 | HDAC1 (0.67) | HDAC1RAB9AROCK2KMT2APOLB | |
| SCHEMBL8913255 | 0.81 | HDAC1 (0.67) | HDAC1RAB9AROCK2KMT2APOLB | |
| SCHEMBL16915097 | 0.80 | ROCK2 (0.62) | HDAC1RAB9AROCK2KMT2APOLB | |
| SCHEMBL16416392 | 0.78 | KMT2A (0.76) | HDAC1KMT2APOLBCYP2D6CYP2C9 | |
| SCHEMBL29450073 | 0.78 | KMT2A (0.76) | HDAC1KMT2APOLBCYP2D6CYP2C9 | |
| SCHEMBL31662444 | 0.78 | RAB9A (0.47) | HDAC1RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL5382057 | 0.77 | HDAC1 (0.55) | HDAC1RAB9AROCK2KMT2APOLB | |
| SCHEMBL22227648 | 0.76 | ROCK2 (0.57) | HDAC1RAB9AROCK2KMT2APOLB | |
| SCHEMBL22227671 | 0.75 | ROCK2 (0.59) | HDAC1RAB9AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1993339-B | Aromatic compound | OTSUKA PHARMA CO LTD | 2013-05-22 | — | — | CN | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| CN-101321529-B | Diaryl aether derivant as antineoplastic agent | OTSUKA PHARMA CO LTD | 2012-09-05 | — | — | CN | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101321529-A | Diaryl aether derivant as antineoplastic agent | OTSUKA PHARMA CO LTD (JP) | 2008-12-10 | — | — | CN | disclosed |
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| CN-1993339-A | Aromatic compound | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | HDAC1 161/4885RAB9A 2782/4885ROCK2 2250/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | HDAC1 6/4885RAB9A 2323/4885ROCK2 1299/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | HDAC1 239/4885RAB9A 3123/4885ROCK2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.